Ramtekkar Ujjwal
Known title: Chief Medical OfficerCIK: 0002009235
Associated companies
Transaction History
| LFST | ▼ Sell | Open Market | 9,519 | $49K | 6/16/2025 | View on chart |
| LFST | ▼ Sell | Open Market | 16,000 | $95K | 6/5/2025 | View on chart |
| LFST | ▼ Sell | Tax Withholding | 4,346 | $31K | 3/10/2025 | View on chart |
| LFST | ▼ Sell | Tax Withholding | 6,544 | $50K | 3/7/2025 | View on chart |
| LFST | ▲ Buy | Grant | 20,805 | $0 | 3/7/2025 | View on chart |
| LFST | ▲ Buy | Grant | 57,107 | $0 | 3/6/2025 | View on chart |
| LFST | ▲ Buy | Grant | 62,413 | $0 | 3/8/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Keybanc Raises LifeStance Health Price Target to $15
Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.
Keybanc Raises LifeStance Health Price Target to $15. Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.